OKYO Pharma Announces Potent Anti-inflammatory Effects of OK-113, a Novel Agonist of Chemerin G-Protein Coupled Receptor, in a Mouse Model of Dry Eye Disease
LONDON–(BUSINESS WIRE)–OKYO Pharma Limited (LSE: OKYO) August 28, 2019, a biotechnology company focusing on the G Protein Coupled Receptors (GPCR)…